{
    "root": "2da839d4-4cba-4ca2-8149-0488263af184",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Linezolid",
    "value": "20250527",
    "ingredients": [
        {
            "name": "LINEZOLID",
            "code": "ISQ9I6J12J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63607"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31404"
        },
        {
            "name": "SODIUM CITRATE, UNSPECIFIED FORM",
            "code": "1Q73Q2JULR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53258"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED",
            "code": "K679OBS311",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85146"
        },
        {
            "name": "ASPARTAME",
            "code": "Z0H242BBR1",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2877"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113455"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        }
    ],
    "indications": {
        "text": "linezolid oxazolidinone-class antibacterial indicated adults children treatment following infections caused susceptible gram-positive bacteria : nosocomial pneumonia ( 1.1 ) ; community-acquired pneumonia ( 1.2 ) ; complicated skin skin structure infections , including diabetic foot infections , without concomitant osteomyelitis ( 1.3 ) ; uncomplicated skin skin structure infections ( 1.4 ) ; vancomycin-resistant enterococcus faecium infections . ( 1.5 ) limitations ( 1.6 ) : \u2022 linezolid indicated treatment gram-negative infections . \u2022 safety efficacy linezolid formulations given longer 28 days evaluated controlled trials . reduce development drug-resistant bacteria maintain effectiveness linezolid formulations antibacterial drugs , linezolid used treat prevent infections proven strongly suspected caused bacteria . ( 1.7 )",
        "doid_entities": [
            {
                "text": "pneumonia (DOID:552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_552"
            },
            {
                "text": "osteomyelitis (DOID:1019)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1019"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": ", route , frequency infection pediatric patients ( birth 11 years age ) adults adolescents ( 12 years older ) duration ( days ) nosocomial pneumonia 10 mg/kg intravenous oral every 8 hours 600 mg intravenous oral every 12 hours 10 14 community-acquired pneumonia , including concurrent bacteremia complicated skin skin structure infections vancomycin-resistant enterococcus faecium infections , including concurrent bacteremia 10 mg/kg intravenous oral every 8 hours 600 mg intravenous oral every 12 hours 14 28 uncomplicated skin skin structure infections less 5 yrs : 10 mg/kg oral every 8 hours 5\u201311 yrs : 10 mg/kg oral every 12 hours adults : 400 mg oral every 12 hours adolescents : 600 mg oral every 12 hours 10 14",
        "doid_entities": [
            {
                "text": "pneumonia (DOID:552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_552"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "linezolid oral suspension available dry , white off-white , orange-flavored granule/powder . constituted directed , bottle contain 150 ml suspension providing equivalent 100 mg linezolid per 5 ml . linezolid oral suspension supplied follows : 100 mg/5 ml 240 ml glass bottles ndc 59762-1308-1 100 mg/5 ml 240 ml glass bottles ndc 59762-1308-4",
    "adverseReactions": "\u2022 known hypersensitivity linezolid product components . ( 4.1 ) \u2022 patients taking monoamine oxidase inhibitors ( maoi ) within two weeks taking maoi . ( 4.2 )",
    "indications_original": "Linezolid is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Uncomplicated skin and skin structure infections ( 1.4 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.5 ) Limitations of Use ( 1.6 ): \u2022 Linezolid is not indicated for the treatment of Gram-negative infections. \u2022 The safety and efficacy of linezolid formulations given for longer than 28 days have not been evaluated in controlled clinical trials. To reduce the development of drug-resistant bacteria and maintain the effectiveness of linezolid formulations and other antibacterial drugs, linezolid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.7 )",
    "contraindications_original": "Dosage, Route, and Frequency of Administration Infection Pediatric Patients (Birth through 11 years of Age) Adults and Adolescents (12 years and Older) Duration (days) Nosocomial pneumonia 10 mg/kg intravenous or oral every 8 hours 600 mg intravenous or oral every 12 hours 10 to 14 Community-acquired pneumonia, including concurrent bacteremia Complicated skin and skin structure infections Vancomycin-resistant Enterococcus faecium infections , including concurrent bacteremia 10 mg/kg intravenous or oral every 8 hours 600 mg intravenous or oral every 12 hours 14 to 28 Uncomplicated skin and skin structure infections less than 5 yrs: 10 mg/kg oral every 8 hours 5\u201311 yrs: 10 mg/kg oral every 12 hours Adults: 400 mg oral every 12 hours Adolescents: 600 mg oral every 12 hours 10 to 14",
    "warningsAndPrecautions_original": "Linezolid for Oral Suspension is available as a dry, white to off-white, orange-flavored granule/powder. When constituted as directed, each bottle will contain 150 mL of a suspension providing the equivalent of 100 mg of linezolid per each 5 mL. Linezolid for Oral Suspension is supplied as follows:\n                  100 mg/5 mL in 240 mL glass bottles\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 59762-1308-1\n                  100 mg/5 mL in 240 mL glass bottles\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 59762-1308-4",
    "adverseReactions_original": "\u2022 Known hypersensitivity to linezolid or any of the other product components. ( 4.1 ) \u2022 Patients taking any monoamine oxidase inhibitors (MAOI) or within two weeks of taking an MAOI. ( 4.2 )",
    "drug": [
        {
            "name": "Linezolid",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63607"
        }
    ]
}